PharmEasy-Owned Thyrocare Q2 Profit Soars 81% YoY To INR 48 Crore

PharmEasy-Owned Thyrocare Q2 Profit has jumped a remarkable 81% year-on-year to INR 47.8 crore in Q2 FY26, up from INR 26.4 crore in the same period last year. The diagnostic giant, owned by PharmEasy, continues to outperform expectations on both revenue and profitability metrics, showcasing its strong business fundamentals amid a competitive healthcare market.

On a sequential basis, PharmEasy-Owned Thyrocare Q2 Profit rose 25% compared to INR 38.3 crore in Q1 FY26. This sharp rise was supported by solid revenue growth, operational efficiency, and improved EBITDA margins.

Revenue Growth Fuels PharmEasy-Owned Thyrocare Q2 Profit

The company’s operating revenue climbed to INR 216.5 crore during the quarter, marking a 22% year-on-year jump from INR 177.4 crore in Q2 FY25. Sequentially, the revenue grew 12% from INR 193 crore, reflecting sustained momentum across its core business segments.

According to the company’s statement, the top-line growth was primarily driven by a 24% surge in its pathology segment. Within this vertical, franchise revenue increased 20% YoY while partnership revenue saw an impressive 35% YoY jump. This strong performance in diagnostic testing services was the key contributor to the rise in PharmEasy-Owned Thyrocare Q2 Profit.

Operational Performance and EBITDA Margins

During Q2 FY26, the company’s EBITDA grew 48% year-on-year to INR 71.5 crore, with margins expanding by 600 basis points to 33%. Including other income of INR 3.1 crore, total income for the quarter stood at INR 219.6 crore.

Meanwhile, total expenses increased modestly by 10% YoY and 7% QoQ to INR 157.3 crore — highlighting Thyrocare’s effective cost management strategies. The company also reported record operational performance, processing 5.33 crore diagnostic tests, marking a 21% YoY increase.

These figures reinforce the strength of PharmEasy-Owned Thyrocare Q2 Profit, positioning it as one of the most efficient and profitable diagnostics brands in India’s healthcare sector.

Dividend and Bonus Share Announcement

In addition to reporting stellar financial results, Thyrocare’s board announced an interim dividend of INR 7 per share for FY26. It also approved a bonus share issue in a 2:1 ratio — offering two equity shares for every one share held by existing shareholders.

This shareholder-friendly move reflects the management’s confidence in the company’s financial stability and growth prospects following the record-breaking PharmEasy-Owned Thyrocare Q2 Profit.

Parent Company PharmEasy Faces Ongoing Challenges

While Thyrocare continues to deliver strong results, its parent company PharmEasy is still navigating financial headwinds. During the same quarter, PharmEasy secured a debt facility of INR 1,700 crore to manage past obligations. To raise funds, its subsidiary Docon Technologies pledged 3.23 crore Thyrocare shares to Catalyst Trusteeship Ltd.

Additionally, leadership changes took place during the quarter — founder Siddharth Shah stepped down as CEO, and Thyrocare’s Guha succeeded him as the new PharmEasy CEO. Despite these challenges, PharmEasy-Owned Thyrocare Q2 Profit stands out as a bright spot in the group’s portfolio.

PharmEasy-Owned Thyrocare Q2 Profit Signals Strength in Diagnostics Sector

The outstanding performance of PharmEasy-Owned Thyrocare Q2 Profit underscores the resilience of India’s diagnostics and preventive healthcare industry. With consistent revenue growth, margin expansion, and shareholder value creation, Thyrocare remains a leading name in the sector.

As India’s demand for reliable and affordable diagnostics rises, Thyrocare’s continued innovation and franchise expansion will be key drivers for future profitability.

Stay Updated with KuberGrow

For investors tracking the healthcare and diagnostics sector, KuberGrow provides real-time insights, unlisted share opportunities, and performance trends of market leaders like Thyrocare, PharmEasy, and others.

Visit KuberGrow.com to explore unlisted pre-IPO opportunities, sectoral updates, and data-driven market insights before they hit the mainstream. Stay ahead of the curve — invest smarter with KuberGrow.